MetaCap

Acurx Pharmaceuticals (ACXP) vs FibroBiologics (FBLG)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

FibroBiologics is the larger company by market cap ($6.3 million vs $6.3 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ACXP-20.00%FBLG-38.16%
+2%-19%-40%
Oct 7, 20261 yearNov 20, 2026
ACXP-18.11%FBLG-37.61%
+2%-19%-39%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ACXP versus FBLG key metrics
MetricACXPFBLG
Share price$1.04$0.705
Market cap$6.30M$6.34M
1-day change+0.97%-15.06%
EPS (TTM)$-1.90$-2.51
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-7.97M$-18.65M
52-week high$7.54$9.60
52-week low$0.90$0.62
Distance from 52-week high-86.21%-92.66%
Analyst consensusstrong_buynone
Avg. price target upside+1534.62%+1673.05%
Average volume97.29K160.05K
Shares outstanding6.06M8.99M
Employees415
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Acurx Pharmaceuticals

ACXP stock →

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.

Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees

About FibroBiologics

FBLG stock →

FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis.

Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees

ACXP vs FBLG FAQ

Which is bigger, Acurx Pharmaceuticals or FibroBiologics?

FibroBiologics (FBLG) is larger, with a market capitalization of $6.34M compared with $6.30M for Acurx Pharmaceuticals (ACXP).

Are Acurx Pharmaceuticals and FibroBiologics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons